ES2588190T3 - Utilización de ácido hialurónico para la preparación de composiciones destinadas a la mejora de la función de protección de la piel, del ojo y de las mucosas - Google Patents
Utilización de ácido hialurónico para la preparación de composiciones destinadas a la mejora de la función de protección de la piel, del ojo y de las mucosas Download PDFInfo
- Publication number
- ES2588190T3 ES2588190T3 ES08827623.3T ES08827623T ES2588190T3 ES 2588190 T3 ES2588190 T3 ES 2588190T3 ES 08827623 T ES08827623 T ES 08827623T ES 2588190 T3 ES2588190 T3 ES 2588190T3
- Authority
- ES
- Spain
- Prior art keywords
- hyaluronic acid
- eye
- intestinal mucosa
- daltons
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Otolaryngology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0705349 | 2007-07-23 | ||
| FR0705349A FR2919185B1 (fr) | 2007-07-23 | 2007-07-23 | Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de l'etat des muqueuses |
| PCT/FR2008/000959 WO2009024677A2 (fr) | 2007-07-23 | 2008-07-04 | Utilisation d'acide hyaluronique pour la preparation de compositions destinees a l'amelioration notamment de la fonction de protection de la peau, de l'oeil et des muqueuses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2588190T3 true ES2588190T3 (es) | 2016-10-31 |
Family
ID=39088885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08827623.3T Active ES2588190T3 (es) | 2007-07-23 | 2008-07-04 | Utilización de ácido hialurónico para la preparación de composiciones destinadas a la mejora de la función de protección de la piel, del ojo y de las mucosas |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8895532B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2167102B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010534225A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20100059786A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101801391B (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0814446A2 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2588190T3 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2919185B1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009024677A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024194437A1 (en) * | 2023-03-22 | 2024-09-26 | Institut National de la Santé et de la Recherche Médicale | Use of low molecular weight hyaluronic acid for promoting ciliated cell differentiation |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010003797A1 (en) * | 2008-07-09 | 2010-01-14 | Novozymes Biopharma Dk A/S | Hyaluronic acid for corneal wound healing |
| FR2963240B1 (fr) * | 2010-07-28 | 2013-03-15 | Horus Pharma | Composition a usage topique sans conservateur comprenant de l'acide hyaluronique |
| RU2624239C2 (ru) | 2011-06-03 | 2017-07-03 | Аллерган, Инк. | Составы кожного наполнителя, включая антиоксиданты |
| US20130096081A1 (en) | 2011-06-03 | 2013-04-18 | Allergan, Inc. | Dermal filler compositions |
| US9408797B2 (en) | 2011-06-03 | 2016-08-09 | Allergan, Inc. | Dermal filler compositions for fine line treatment |
| US9393263B2 (en) | 2011-06-03 | 2016-07-19 | Allergan, Inc. | Dermal filler compositions including antioxidants |
| HUE037474T2 (hu) * | 2011-07-07 | 2018-08-28 | Holy Stone Healthcare Co Ltd | Készítmény gyulladással kapcsolatban rendellenesség kezelésében és megelõzésében történõ alkalmazásra |
| TWI466675B (zh) | 2011-09-16 | 2015-01-01 | Univ China Medical | 用於抑制發炎之醫藥組合物 |
| CN102669681A (zh) * | 2012-06-09 | 2012-09-19 | 东莞市照燕生物科技有限公司 | 一种保护胃肠粘膜的营养保健品 |
| WO2014063735A1 (en) | 2012-10-25 | 2014-05-01 | Mdt Int'l S.A. | Mucoadhesive compositions comprising hyaluronic acid and chitosan for topical application |
| JP2015063510A (ja) * | 2013-06-28 | 2015-04-09 | キユーピー株式会社 | 肌の保湿機能向上に関わる保湿関連遺伝子発現促進剤 |
| EP3328353B1 (en) | 2015-07-27 | 2024-04-10 | Mary Kay, Inc. | Topical skin formulations |
| JP6718728B2 (ja) * | 2016-04-06 | 2020-07-08 | キユーピー株式会社 | アンチポリューション剤およびアンチポリューション用皮膚外用組成物 |
| US20210000910A1 (en) | 2019-07-03 | 2021-01-07 | Jysk Skin Solutions Pte Ltd | Topical compositions |
| WO2022236585A1 (zh) * | 2021-05-10 | 2022-11-17 | 傅毓秀 | 玻尿酸用于制备治疗肺纤维化药剂的用途 |
| TWI816119B (zh) * | 2021-05-10 | 2023-09-21 | 國立陽明交通大學 | 玻尿酸用於製備治療急性呼吸窘迫症藥劑之用途 |
| WO2022236599A1 (zh) * | 2021-05-10 | 2022-11-17 | 傅毓秀 | 玻尿酸用于制备治疗急性呼吸窘迫症药剂的用途 |
| CN115317504A (zh) * | 2021-05-10 | 2022-11-11 | 傅毓秀 | 玻尿酸用于制备治疗急性呼吸窘迫症药剂的用途 |
| EP4426317A1 (en) * | 2021-11-05 | 2024-09-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of low molecular weight hyaluronic acid for the treatment of lung mucosal inflammation |
| US12083204B2 (en) | 2022-06-02 | 2024-09-10 | L'oreal | Topical composition for homeostatic delivery of nitric oxide and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4303676A (en) * | 1980-03-21 | 1981-12-01 | Balazs Endre A | Hyaluronate based compositions and cosmetic formulations containing same |
| US5166331A (en) * | 1983-10-10 | 1992-11-24 | Fidia, S.P.A. | Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same |
| US4517295A (en) * | 1983-02-18 | 1985-05-14 | Diagnostic, Inc. | Hyaluronic acid from bacterial culture |
| JPS59219209A (ja) * | 1983-05-28 | 1984-12-10 | Kanebo Ltd | 皮膚化粧料 |
| IT1260148B (it) * | 1992-04-17 | 1996-03-28 | Fidia Spa | Impiego di preparazioni di acido ialuronico per la formazione di tessuto osseo |
| ITPD980168A1 (it) * | 1998-07-06 | 2000-01-06 | Fidia Advanced Biopolymers Srl | Composizioni biocompatibili e biodegradabili comprendenti acido ialuronico e suoi derivati per il trattamento delle ulcere dell'appara |
| DE10111165A1 (de) * | 2001-03-02 | 2002-10-10 | Knoell Hans Forschung Ev | Verwendung von Hyaluronsäure-Uroniden zur Behandlung von entzündlichen Vorgängen |
| DE10161149B4 (de) * | 2001-12-12 | 2007-03-08 | Ursapharm Arzneimittel Gmbh & Co. Kg | Verwendung von Heparin-haltigem Ophthalmikum |
| DE10161110A1 (de) * | 2001-12-12 | 2003-06-26 | Ursapharm Arzneimittel Gmbh | Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung |
| US7241456B2 (en) * | 2002-10-25 | 2007-07-10 | Australian Importers Ltd. | Formulations for topical delivery of bioactive substances and methods for their use |
| FR2847818B1 (fr) * | 2002-11-28 | 2008-04-04 | Agro Ind Rech S Et Dev Ard | Composition pharmaceutique a base d'acide hyaluronique |
| WO2006072243A1 (en) * | 2005-01-03 | 2006-07-13 | Novozymes Biopolymer A/S | Hyaluronic acid fraction with moisturizing and anti-wrinkle properties |
| JP4576583B2 (ja) * | 2005-03-22 | 2010-11-10 | キユーピー株式会社 | ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物 |
-
2007
- 2007-07-23 FR FR0705349A patent/FR2919185B1/fr active Active
-
2008
- 2008-07-04 KR KR1020107001664A patent/KR20100059786A/ko not_active Ceased
- 2008-07-04 JP JP2010517434A patent/JP2010534225A/ja not_active Ceased
- 2008-07-04 ES ES08827623.3T patent/ES2588190T3/es active Active
- 2008-07-04 BR BRPI0814446-0A2A patent/BRPI0814446A2/pt not_active IP Right Cessation
- 2008-07-04 WO PCT/FR2008/000959 patent/WO2009024677A2/fr not_active Ceased
- 2008-07-04 EP EP08827623.3A patent/EP2167102B1/fr active Active
- 2008-07-04 US US12/670,219 patent/US8895532B2/en active Active
- 2008-07-04 CN CN2008801063138A patent/CN101801391B/zh not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024194437A1 (en) * | 2023-03-22 | 2024-09-26 | Institut National de la Santé et de la Recherche Médicale | Use of low molecular weight hyaluronic acid for promoting ciliated cell differentiation |
Also Published As
| Publication number | Publication date |
|---|---|
| US8895532B2 (en) | 2014-11-25 |
| CN101801391A (zh) | 2010-08-11 |
| HK1145149A1 (en) | 2011-04-08 |
| WO2009024677A3 (fr) | 2009-12-03 |
| JP2010534225A (ja) | 2010-11-04 |
| BRPI0814446A2 (pt) | 2015-01-06 |
| FR2919185B1 (fr) | 2010-09-10 |
| EP2167102B1 (fr) | 2016-05-25 |
| KR20100059786A (ko) | 2010-06-04 |
| EP2167102A2 (fr) | 2010-03-31 |
| CN101801391B (zh) | 2013-07-10 |
| US20100210585A1 (en) | 2010-08-19 |
| FR2919185A1 (fr) | 2009-01-30 |
| WO2009024677A2 (fr) | 2009-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8895532B2 (en) | Use of hyaluronic acid for the preparation of compositions intended for improving in particular the protective function of the skin, the eye and the mucous membranes | |
| Kong et al. | Restore intestinal barrier integrity: an approach for inflammatory bowel disease therapy | |
| ES2773017T3 (es) | Derivados de quitosano para el tratamiento de mucositis o ulceración | |
| Antwi et al. | Stigmasterol Modulates Allergic Airway Inflammation in Guinea Pig Model of Ovalbumin‐Induced Asthma | |
| EP2545925B1 (en) | Compositions comprising hyaluronic acid for treating and preventing mucosa related diseases | |
| Barroso et al. | Propolis reversed cigarette smoke-induced emphysema through macrophage alternative activation independent of Nrf2 | |
| TWI913236B (zh) | 新多功能寡肽 | |
| Takhshid et al. | The healing effect of licorice extract in acetic acid-induced ulcerative colitis in rat model | |
| Wigenstam et al. | Acute respiratory changes and pulmonary inflammation involving a pathway of TGF-β1 induction in a rat model of chlorine-induced lung injury | |
| ES2527096T3 (es) | Combinación de ADNasa I y glucosaminoglucanos para su uso en limpieza de ADN extracelular | |
| CN104292305B (zh) | 一种多肽、制备方法及其应用 | |
| Xi et al. | Establishment and characterization of murine models of asthma and subcutaneous immunotherapy for Humulus pollen allergy | |
| Allon et al. | Inhalation exposure to sulfur mustard in the guinea pig model: clinical, biochemical and histopathological characterization of respiratory injuries | |
| Chen et al. | Unraveling the mechanisms underlying air pollution-induced dysfunction of the oral–gut–brain axis: implications for human health and well-being | |
| CN111135141A (zh) | 一种鼻腔用复合水凝胶制备方法 | |
| Di Cicco et al. | Hyaluronic acid for the treatment of airway diseases in children: Little evidence for few indications | |
| ES2315479T3 (es) | Empleo de glicosaminoglicanos tales como p.ej.heparina para el tratamiento de trastornos respiratorios tales como copd. | |
| TWI480044B (zh) | A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution | |
| ES2754436T3 (es) | Composiciones y métodos para usar cuerpos laminares para propósitos terapéuticos | |
| CN112074291A (zh) | 预防和治疗呼吸道疾病的组合物 | |
| Bentivegna et al. | The linkage between upper respiratory tract infections and otitis media: evidence of the ‘united airways concept | |
| Zeitlin et al. | Protein processing and degradation in pulmonary health and disease | |
| Qiu et al. | Nrf2 Improves Airway Goblet Cell Metaplasia in Chronic Obstructive Pulmonary Disease (COPD) and Its Mechanism | |
| HK1145149B (en) | Use of hyaluronic acid for preparing compositions for improving the function of skin, eye and mucous membrane protection | |
| US10035821B2 (en) | Calcium binding compounds based on gamma-carboxy glutamate |